Almost two years after finally pulling the plug on a big non-opioid painkiller programme, Eli Lilly has ... royalty rate. Lilly’s last attempt to develop a non-opioid pain drug was with Pfizer ...

Eli Lilly’s new chief executive David Ricks has made his first acquisition, bringing in biotech CoLucid for $960 million – reacquiring a migraine drug the big pharma sold off 12 years ago.

Alvidrez’s son, also named Steven, said they got the news of Lilly’s arrest two nights ago. The courtroom Friday afternoon was absolutely packed as dozens showed up to support the Alvidrez ...

Eli Lilly's Chief Scientific Officer Dan Skovronsky says the company wants to take big swings in Alzheimer's, ALS, chronic pain and other difficult diseases after its success in obesity.

Eli Lilly & Co. said Tuesday it’s cutting the price of single-dose vials of its Zepbound treatment for diabetes and obesity for patients who have to pay for the drug themselves. It said it will ...